Cross Icon

TRC Plus for Hemophilia

Cross Icon
Happy son rides on dad's shoulders outside in green field

Make hemophilia more predictable and affordable

Hemophilia is a genetic, incurable bleeding disorder affecting 30,000 males in the United States1. The care journey for and costs associated with hemophilia are often unpredictable, complex, and expensive for plans and patients. Individualized treatment plans can include clotting factor injections, monoclonal antibodies, or even gene therapies.

1. Institute for Clinical and Economic Review, Sept. 2022

Total cost and care for hemophilia

100%

in-market factor therapy and gene therapy access through Accredo, ensuring continuity of patient care2

2. Accredo BoB blended factor discount averages for 2022, based on 500k life client and payers who were not previously enrolled in exclusive Accredo arrangements. While these factor figures are average, actual patient spend can vary widely.

$1.8M

aggregate savings driven through proprietary hemophilia-specific TRC waste management protocols3

3. Journal of Managed Care & Specialty Pharmacy: Vol 29, No 1, Jan, 2023. “Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste”. www.jmcp.org/doi/full/10.18553/jmcp.2023.29.1.47

Hemophilia designed support

Realize plan savings and drive a better patient experience with capabilities such as:
A self-service dashboard

to review therapy utilizations and gene therapy forecasting that projects potential impact to plan.

Therapy discounts across all hemophilia treatment options

including gene therapies at cost, and an average annual savings of $200K on non-gene therapies.4

4. Journal of Managed Care & Specialty Pharmacy: Vol 29, No 1, Jan, 2023. “Optimizing maintenance dosing of emicizumab-kxwh as  prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste”. www.jmcp.org/doi/full/10.18553/jmcp.2023.29.1.47

A comprehensive care model

with dedicated TRC specialists, in-home and virtual care options, and multi-level waste reduction through our Blood Disorder TRC.

Navigation assistance

to guide patients through coverage policies and utilization management requirements for gene therapies.

Cross Icon
Cross Icon
Achieve higher predictability and transparency for your hemophilia population today
Cross Icon
Cross Icon
Explore more